{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Vaubel RA"],"funding":["HHS | National Institutes of Health","Alpha Omega Alpha Carolyn L. Kuckein Student Research Fellowship","NHLBI NIH HHS","Mayo Clinic","NCI NIH HHS","NINDS NIH HHS","Accelerate Brain Cancer Cure"],"pagination":["1094-1104"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7056576"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["26(5)"],"pubmed_abstract":["<h4>Purpose</h4>Glioblastoma is the most frequent and lethal primary brain tumor. Development of novel therapies relies on the availability of relevant preclinical models. We have established a panel of 96 glioblastoma patient-derived xenografts (PDX) and undertaken its genomic and phenotypic characterization.<h4>Experimental design</h4>PDXs were established from glioblastoma, IDH-wildtype (<i>n</i> = 93), glioblastoma, IDH-mutant (<i>n</i> = 2), diffuse midline glioma, H3 K27M-mutant (<i>n</i> = 1), and both primary (<i>n</i> = 60) and recurrent (<i>n</i> = 34) tumors. Tumor growth rates, histopathology, and treatment response were characterized. Integrated molecular profiling was performed by whole-exome sequencing (WES, <i>n</i> = 83), RNA-sequencing (<i>n</i> = 68), and genome-wide met"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma."],"pmcid":["PMC7056576"],"funding_grant_id":["P50 CA108961","R24 NS092940","U01 CA227954","R35 CA197745","R01 CA230712","P30 CA015083","U01 CA217858","RO1 CA184320","R01 CA184320","R25 HL092621"],"pubmed_authors":["Peng S","Carlson BL","Dhruv HD","Kitange GJ","Kollmeyer TM","Remonde D","Mladek AC","Evers L","Marin BM","Grove R","Wang Q","Giannini C","Ma DJ","Jenkins RB","Sulman EP","Berens ME","Meyer FB","Sarkar G","Verhaak RG","Schroeder MA","Parney IF","O'Neill BP","Klee EW","Tran NL","Eckel-Passow JE","Vaubel RA","Califano A","LaChance DH","Caron A","Tian S","Burns TC","Decker PA","Yan H","Sarkaria JN"],"additional_accession":[]},"is_claimable":false,"name":"Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma.","description":"<h4>Purpose</h4>Glioblastoma is the most frequent and lethal primary brain tumor. Development of novel therapies relies on the availability of relevant preclinical models. We have established a panel of 96 glioblastoma patient-derived xenografts (PDX) and undertaken its genomic and phenotypic characterization.<h4>Experimental design</h4>PDXs were established from glioblastoma, IDH-wildtype (<i>n</i> = 93), glioblastoma, IDH-mutant (<i>n</i> = 2), diffuse midline glioma, H3 K27M-mutant (<i>n</i> = 1), and both primary (<i>n</i> = 60) and recurrent (<i>n</i> = 34) tumors. Tumor growth rates, histopathology, and treatment response were characterized. Integrated molecular profiling was performed by whole-exome sequencing (WES, <i>n</i> = 83), RNA-sequencing (<i>n</i> = 68), and genome-wide met","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Mar","modification":"2026-05-04T19:59:39.135Z","creation":"2020-09-05T07:14:38Z"},"accession":"S-EPMC7056576","cross_references":{"pubmed":["31852831"],"doi":["10.1158/1078-0432.CCR-19-0909","10.1158/1078-0432.ccr-19-0909"]}}